Cancer

Glioblastoma Foundation(R) Announces the Establishment of Groundbreaking Genomic Testing & Research Laboratory

DURHAM, NC / ACCESSWIRE / May 15, 2024 / The Glioblastoma Foundation announced today the establishment of a pioneering Genomic…

4 weeks ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15,…

4 weeks ago

Lynx.MD Partners with New York Gastroenterology Associates to Enhance Gastrointestinal Research Efforts

Strategic Partnership Reveals Untapped Insights in Gastroenterology Data for Research Advancement PALO ALTO, CA / ACCESSWIRE / May 15, 2024…

4 weeks ago

First 1,000 Days Suncoast Initiative Powered by Unite Us Increases Access to Vital Support Services by 89%, Leading to 54% Reduction in Stress for Families in Need

New evaluation highlights an average increase of four mentally healthy days per month for expecting parents and families with young…

4 weeks ago

White House Highlights National Minority Quality Forum in Progress Report on Biden Cancer Moonshot

Washington, D.C.--(Newsfile Corp. - May 15, 2024) - The National Minority Quality Forum (NMQF), a non-profit health care research, education…

4 weeks ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

4 weeks ago

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

4 weeks ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived…

4 weeks ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic…

4 weeks ago

Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care

NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research…

4 weeks ago